MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
October 25-26, 2023

**Wednesday, October 25, 2023**

8:00  Welcome & Introductions

Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:30  Meningococcal Vaccines

**Introduction**

**Plan for revisiting adolescent schedule for meningococcal vaccines**

**Comparison of Pfizer and CDC cost effectiveness analyses**

**Summary of EtR and proposed recommendations for Pfizer’s MenABCWY vaccine**

Vaccines for Children Resolution

Dr. Kathy Poehling (ACIP, WG Chair)
Dr. Lucy McNamara (CDC/NCIRD)
Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
Dr. Jennifer Collins (CDC/NCIRD)

10:10  Break

10:25  Mpox Vaccines

**Introduction**

Updates about U.S. mpox epidemiology, vaccine safety, and vaccine effectiveness

Evidence to recommendations framework

Review of voting language and clinical guidance

Vaccines for Children resolution

Dr. Pablo Sanchez (ACIP, WG Chair)
Dr. Faisal Minhaj (CDC/NCEZID)
Dr. Agam Rao (CDC/NCEZID)
Dr. Jeanne Santoli (CDC/NCIRD)

12:15  Break

12:45  Public Comment

1:00  VOTES

**Meningococcal Vote**

**Meningococcal VFC Vote**

**Mpox Vote**

**Mpox VFC Vote**

Dr. Jennifer Collins (CDC/NCIRD)
Dr. Jeanne Santoli (CDC/NCIRD)
Dr. Agam Rao (CDC/NCEZID)
Dr. Jeanne Santoli (CDC/NCIRD)

1:30  Break

1:45  RSV - Adults

**Introduction**

GSK safety and immunogenicity in persons 50-59 years of age

Epidemiology of RSV in adults

Work group interpretation and ACIP discussion

Dr. Camille Kotton (ACIP, WG Chair)
Dr. Susan Gerber (GSK)
Dr. Monica Patton (CDC/NCIRD)
Dr. Amadea Britton (CDC/NCIRD)

3:00  Influenza Vaccines

**Introduction**

Safety of quadrivalent recombinant influenza vaccine in pregnant women and their infants

Pregnancy outcomes with ccIIV4 (Flucelvax): results of a post-marketing study

Safety of simultaneous versus sequential administration of mRNA COVID-19 and Quadrivalent Inactivated Influenza (IIV4) Vaccines: A randomized placebo controlled trial

Safety of simultaneous vaccination with Zoster Vaccine Recombinant (RZV) and quadrivalent Adjuvanted Inactivated Influenza Vaccine (allV4)

Dr. Jamie Loehr (ACIP, WG Chair)
Dr. Nicky Klein (Kaiser Permanente Northern California)
Dr. Gregg Sylvester (Seqirus)
Dr. Chip Walter (Duke University)
Dr. Ken Schmader (Duke University)

4:30  Vaccine Safety Update

Update on COVID-19 and Influenza Vaccine Safety

Dr. Tom Shimabukuro (CDC/NCEZID)

5:30  Adjourn
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome &amp; Introductions</td>
<td>Dr. Grace Lee (ACIP Chair)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Melinda Wharton (ACIP Executive Secretary, CDC)</td>
</tr>
<tr>
<td>8:10</td>
<td>Agency Updates</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Combined Immunization Schedules</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction to 2024 adult and child/adolescent immunization schedule</td>
<td>Dr. Sybil Cineas (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>2024 child and adolescent schedule revisions</td>
<td>Dr. Patricia Wodi (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>2024 adult schedule revisions</td>
<td>Dr. Neil Murthy (CDC/NCIRD)</td>
</tr>
<tr>
<td>9:50</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Public Comment</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>VOTES Immunization Schedules Vote</td>
<td>Dr. Patricia Wodi (CDC/NCIRD), Dr. Neil Murthy (CDC/NCIRD)</td>
</tr>
<tr>
<td>10:30</td>
<td>Chikungunya Vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>Dr. Beth Bell (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>EtR and proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad</td>
<td>Dr. Susan Hills (CDC/NCEZID)</td>
</tr>
<tr>
<td></td>
<td>EtR and proposed policy options for chikungunya vaccine use among laboratory workers</td>
<td>Dr. Susan Hills (CDC/NCEZID)</td>
</tr>
<tr>
<td>11:40</td>
<td>Dengue Vaccines</td>
<td>Dr. Wilbur Chen (ACIP, WG Chair)</td>
</tr>
<tr>
<td>11:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>COVID-19 Vaccines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>Dr. Matt Daley (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>COVID-19 vaccine implementation</td>
<td>Dr. Shannon Stokley (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>COVID-19 vaccine policy and next steps</td>
<td>Dr. Megan Wallace (CDC/NCIRD)</td>
</tr>
<tr>
<td>12:50</td>
<td>Pneumococcal Vaccines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Work Group Updates and Next Steps</td>
<td>Dr. Miwako Kobayashi (CDC/NCIRD)</td>
</tr>
<tr>
<td>1:00</td>
<td>Influenza Vaccines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effectiveness of maternal influenza vaccination during pregnancy against influenza-associated hospitalizations &amp; emergency department visits in infants &lt;6 Months of Age</td>
<td>Ms. Samantha Olson (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>Update on influenza B/Yamagata surveillance</td>
<td>Dr. Rebecca Kondor (CDC/NCIRD)</td>
</tr>
<tr>
<td>1:40</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Acronyms**

- CDC: Centers for Disease Control and Prevention
- CMS: Centers for Medicare and Medicaid Services
- COVID-19: Coronavirus disease 2019
- EtR: Evidence to Recommendations Framework
- FDA: Food and Drug Administration
- GRADE: Grading of Recommendations Assessment, Development and Evaluation
- HRSA: Health Resources and Services Administration
- IHS: Indian Health Service
- LAIV4: Live Attenuated Influenza Vaccine
- NCHHSTP: National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
- NCIRD: National Center for Immunization & Respiratory Diseases [of CDC/OID]
- NCEZID: National Center for Emerging and Zoonotic Diseases [of CDC/OID]
- NIAID: National Institute of Allergy and Infectious Diseases
- OIDP: Office of Infectious Disease and HIV/AIDS Policy
- SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
- WG: Work Group
- WHO: World Health Organization
- VE: Vaccine Effectiveness